FP129NEWLY ADMINISTERED IMMUNOSUPPRESSIVE THERAPY (IST) HAS NO IMPACT ON LONG-TERM ANTIPROTEINURIC EFFECT OF SPARSENTAN (SPAR), A DUAL ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): INTERIM ANALYSIS OF THE DUET TRIAL
出版年份 2018 全文链接
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started